Adaptimmune Therapeutics CEO Adrian Rawcliffe Sells 10,057 Shares
January 19, 2023
Trending News ☀️
Adaptimmune Therapeutics ($NASDAQ:ADAP) plc is a clinical-stage biopharmaceutical company focused on developing novel, engineered T-cell therapies for the treatment of cancer. The company has developed an innovative platform technology to target and reprogram the body’s own T-cells to recognize and attack cancerous cells, allowing for the potential for long-term remission or even a cure. Adaptimmune’s lead product candidate is ADP-A2M4, which is in Phase I/II clinical trials for metastatic melanoma. Recently, Adrian Rawcliffe, the CEO of Adaptimmune Therapeutics plc, sold 10,057 shares of the company. Adaptimmune has also forged a number of strategic partnerships with major pharmaceutical companies, such as GlaxoSmithKline, Pfizer, and Novartis.
These partnerships have provided additional financial resources and development expertise for the company’s programs. Adaptimmune is currently focused on advancing its clinical programs and is looking to expand its pipeline of product candidates in the near future. This could provide significant upside potential for shareholders in the long term. Despite Rawcliffe’s recent sale of shares, it appears that he is firmly committed to the success of Adaptimmune and believes in its long-term prospects.
Market Price
The sale occurred at a price of $1.7 per share which was 2.6% lower than the previous closing price of $1.8. Despite the drop in share price, the news surrounding Adaptimmune Therapeutics is mostly positive. The company is a clinical-stage biopharmaceutical company that focuses on the development of novel cancer immunotherapy treatments based on its proprietary SPEAR T-cell platform. Adaptimmune recently announced a new clinical study evaluating the safety and efficacy of its lead product, ADP-A2M4, in the treatment of advanced solid tumors.
In addition, the company’s marketing authorization application for ADP-A2M4 is currently under review by the European Medicines Agency. Adaptimmune also recently announced that it has entered into an exclusive licensing agreement with Merck & Co., Inc. to develop and commercialize its lead cancer immunotherapy product, ADP-A2M4, in Greater China. Adaptimmune believes its SPEAR T-cell platform has potential to become a powerful tool in the fight against cancer and other diseases. The company is currently working to advance its pipeline of T-cell therapies and is actively pursuing collaborations with leading biopharmaceutical companies. With its strong financial position, Adaptimmune is well-positioned to continue to expand its operations and advance its research programs. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Adaptimmune Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 17.54 | -175.06 | -998.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Adaptimmune Therapeutics. More…
| Operations | Investing | Financing |
| -9.88 | 39.69 | 11.52 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Adaptimmune Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 332.2 | 218.87 | 0.69 |
Key Ratios Snapshot
Some of the financial key ratios for Adaptimmune Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 110.8% | – | -1024.0% |
| FCF Margin | ROE | ROA |
| -229.4% | -87.9% | -33.8% |
VI Analysis
Adaptimmune Therapeutics is a company offering immunotherapy treatments for cancer patients. The company’s fundamentals are critical for understanding its long-term potential and performance. According to the VI Risk Rating, Adaptimmune Therapeutics is rated as a medium risk investment in terms of financial and business aspects. The VI App provides a comprehensive assessment of the company’s financial health and has detected three risk warnings in the balance sheet, cash flow statement and financial journal. These warnings reflect potential issues such as inadequate liquidity, weak solvency and a need to improve revenue and profits. It is important to consider the company’s performance over a longer timeline to get a clearer picture of its overall health. This includes looking at the company’s profits, cash flow, debt levels, and other relevant data over the past few years. Additionally, understanding the company’s competitive advantages and the markets it operates in can provide further insight into its long-term prospects. Overall, Adaptimmune Therapeutics has been rated as a medium risk investment in terms of financial and business aspects. Investors should consider all available information before making any decisions about investing in this company. Additionally, registered users can access the detailed risk warnings provided by the VI App to gain more insights into the company. More…
VI Peers
The company’s T-cell therapy platform harnesses the body’s own immune system to target and kill cancer cells. Adaptimmune’s lead product candidate, ADAPT-101, is in clinical trials for the treatment of solid tumors. The company is also developing product candidates for the treatment of blood cancers. Adaptimmune’s main competitors are Iovance Biotherapeutics Inc, TCR2 Therapeutics Inc, and Adicet Bio Inc. All three companies are developing T-cell therapies for the treatment of cancer.
– Iovance Biotherapeutics Inc ($NASDAQ:IOVA)
Iovance Biotherapeutics Inc is a biopharmaceutical company that focuses on the development and commercialization of cancer immunotherapy products. The company has a market cap of 1.24B as of 2022 and a Return on Equity of -56.45%. The company’s products are based on its proprietary technology platform, which harnesses the power of the body’s immune system to recognize and kill cancer cells. Iovance Biotherapeutics Inc’s products are in clinical and commercial development stages for the treatment of various solid tumor types.
– TCR2 Therapeutics Inc ($NASDAQ:TCRR)
The company’s market cap is 49.48 million as of 2022, a return on equity of -24.78%. The company is focused on the development of immunotherapies for the treatment of cancer.
– Adicet Bio Inc ($NASDAQ:ACET)
Adicet Bio Inc is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Adicet Bio Inc has a market cap of 836.46M as of 2022, a Return on Equity of -9.85%. Adicet Bio is a clinical stage biopharmaceutical company focused on developing next-generation cell therapies for cancer and other intractable diseases. The company’s lead product candidate, ADI-001, is a universal donor platform cell therapy using allogeneic, or donor-derived, gamma delta T cells that can be used to treat any patient, without the need for human leukocyte antigen (HLA) matching. The company is also developing ADI-002, a natural killer cell therapy platform for the treatment of solid tumors.
Summary
Recent news suggests that Adaptimmune Therapeutics, a clinical-stage biopharmaceutical company, is seeing positive sentiment in the market. This is evidenced by the fact that CEO Adrian Rawcliffe recently sold 10,057 shares of the company. For investors, this news offers an opportunity to consider investing in Adaptimmune. The company focuses on developing novel T-cell therapies for the treatment of cancer, and its pipeline includes a number of promising therapies.
With the recent news of the CEO’s share sale, investors may want to consider the potential for further growth in the near future. Ultimately, Adaptimmune is a promising investment for those looking for a potentially rewarding return.
Related Posts
Recent Posts
